SAN DIEGO--(BUSINESS WIRE)--Batu Biologics, an immunotherapy company developing the ValloVax™ anti-angiogenic lung cancer vaccine, announced today the addition Dr. Davorka Messmer to its Scientific Advisory Board (SAB).
Dr. Messmer will accelerate the clinical development of the company’s cancer vaccine platform, which trains the immune system to selectively destroy the tumor-associated blood vessels. Batu Biologics plans to file an Investigational New Drug (IND) application to the FDA in the first quarter of 2015, seeking approval to enter Phase I clinical trials for lung cancer.
Help employers find you! Check out all the jobs and post your resume.
Dr. Messmer will accelerate the clinical development of the company’s cancer vaccine platform, which trains the immune system to selectively destroy the tumor-associated blood vessels. Batu Biologics plans to file an Investigational New Drug (IND) application to the FDA in the first quarter of 2015, seeking approval to enter Phase I clinical trials for lung cancer.
Help employers find you! Check out all the jobs and post your resume.
